Royal Boskalis Westminster N.V. : In an upward trend
January 25, 2013 at 03:47 am EST
By
Entry price | Target | Stop-loss | Potential |
---|
€34.08 |
€38.29 |
€33.7 |
+12.37% |
---|
Boskalis share could exceed the symbolic threshold of EUR 34.8.
The fundamental qualities of the group are clearly attractive as evidenced by the upward revisions of earnings per share and revenue estimations. The profitability of the company's business remains good. The high levels of valuation show the interest of investors for this security.
Graphically, the security is on a consolidation phase. It seems able to continue this uptrend supported by moving averages and will soon test the EUR 34.8 mid-term resistance. We anticipate a crossing of this level, given the upward orientation of the stock in the medium and long term. Above EUR 34.8, a buy signal will be given.
Exceeding the technical line at EUR 34.8 would point to ambitious upward targets. In this case, market participants could buy this stock with an initial target of EUR 38. If investors reduce long-side exposure for profit-taking, a bearish trend would happen below EUR 33.95 and so this strategy would be invalidated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.